122 search results for: chronic inflammation

Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
Dermatology
Beyond the Visible: The Cumulative Burden of Prurigo Nodularis
expert video

Professor Matthias Augustin emphaizes that prurigo nodularis is a chronic systemic disease with a significant and multifaceted burden, encompassing both visible skin manifestations and hidden psychosocial and physical comorbidities.

View more
thumbnail
Congress
17
May
2026
Congress
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth #1301 brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

Role of Type 2 Cytokines in Asthma and COPD
Type 2 Inflammation
Role of Type 2 Cytokines in Asthma and COPD
expert video

Dr Mario Castro explains how type 2 cytokines play a crucial role in airway remodeling and inflammation in asthma and COPD, impacting patient outcomes.

View more
Event Page Thumbnail
Congress
27
April
2026
Congress
ADVENT at CEORL-HNS 2026

Join Sanofi and Regeneron for an educational symposium on type 2 inflammation, patient characteristics predictive of disease recurrence, and emerging real-world evidence for biologics in CRSwNP.

2025 ADVENT Forum | Potential for Disease Modification in the Airway
Type 2 Inflammation
2025 ADVENT Forum | Potential for Disease Modification in the Airway
expert video

Unlock new perspectives on managing chronic airway diseases. Profs. Leonard Bacharier, Eugenio De Corso, Stella Lee, Marc Miravitlles, Celeste Porsbjerg, Klaus Rabe, and Martin Wagenmann – share their collective wisdom and experience on the evolving landscape of therapeutic strategies aimed at truly modifying disease progression, offering renewed hope for patients and practitioners alike.

View more
ADVENT at ATS 2026
On Demand
ADVENT at ATS 2026

At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD.​

Prurigo Nodularis: Type 2 <b>Inflammation</b> Links Neuronal Dysfunction and Fibrosis
Dermatology
Prurigo Nodularis: Type 2 Inflammation Links Neuronal Dysfunction and Fibrosis
interactivity

This infographic highlights how PN is driven by type 2 inflammation, linking immune dysregulation, fibroblast activation, and neuronal dysfunction to nodule formation. It also shows how cytokine-mediated changes in neuronal architecture increase excitability and chronic itch, where resulting lesions and scarring significantly impact patients’ psychological well-being.

View more
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling
Pulmonology
ERS 2024 | The Role of IL-33 in COPD Patho and Its Impact on Disease Remodeling
expert video

Professor Paola Rogliani examines the role of IL-33 in the pathophysiology of COPD, focusing on its contribution to airway inflammation, remodeling, and disease progression.

View more
Type 2 <b>Inflammation</b> Contributes to Itch and Fibrois in PN
Dermatology
Type 2 Inflammation Contributes to Itch and Fibrois in PN
expert video

Join Dr. Kwatra outlining the micro itch cycle involving type 2 cell polarization and cytokines that directly affect fibroblasts to cause more immune dysregulation in PN.

View more
ADVENT Dermatology Symposium in Denver, CO
On Demand
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation

This 2-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.